Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus

详细信息    查看全文

• 作者：Min Joo Kim ; Hye Seung Jung ; Yul Hwang-Bo ; Sun Wook Cho…
• 关键词：Diabetes mellitus ; Continuous glucose monitoring ; Glucose variability ; 1 ; 5 ; anhydroglucitol ; Postprandial glucose excursion
• 刊名：Acta Diabetologica
• 出版年：2013
• 出版时间：August 2013
• 年：2013
• 卷：50
• 期：4
• 页码：505-510
• 全文大小：193KB
• 参考文献：1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-12 CrossRef
  2. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A (2003) Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52:2795-804 CrossRef
  3. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-687 CrossRef
  4. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D (2008) Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57:1349-354 CrossRef
  5. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR (2010) Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 53:562-71 CrossRef
  6. Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C (2011) Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 10:19 CrossRef
  7. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH (2010) Glucose variability; does it matter? Endocr Rev 31:171-82 CrossRef
  8. American Diabetes Association (2011) Standards of medical care in diabetes-011. Diabetes Care 34(Suppl 1):S11–S61
  9. Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H, Wu P, Teng X, Dong Y, Zhou J, Xu H, Zheng J, Li S, Tao T, Jia Y (2010) Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 47:231-36 CrossRef
  10. American Diabetes Association (2001) Postprandial blood glucose. Diabetes Care 24:775-78 CrossRef
  11. Koga M, Saito H, Mukai M, Matsumoto S, Kasayama S (2010) Influence of iron metabolism indices on glycated haemoglobin but not glycated albumin levels in premenopausal women. Acta Diabetol 47:65-9 CrossRef
  12. Koga M, Murai J, Saito H, Mukai M, Kasayama S (2010) Serum glycated albumin, but not glycated haemoglobin, is low in relation to glycemia in hyperuricemic men. Acta Diabetol 47:173-77 CrossRef
  13. Lee EY, Lee BW, Kim D, Lee YH, Kim KJ, Kang ES, Cha BS, Lee EJ, Lee HC (2010) Glycated albumin is a useful glycation index for monitoring fluctuating and poorly controlled type 2 diabetic patients. Acta Diabetol (in press)
  14. Koga M, Saito H, Mukai M, Otsuki M, Kasayama S (2009) Serum glycated albumin levels are influenced by smoking status, independent of plasma glucose levels. Acta Diabetol 46:141-44 CrossRef
  15. Suwa T, Ohta A, Matsui T, Koganei R, Kato H, Kawata T, Sada Y, Ishii S, Kondo A, Murakami K, Katabami T, Tanaka Y (2010) Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr J 57:135-40 CrossRef
  16. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB (2003) Serum 1, 5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 5:355-63 CrossRef
  17. Yamanouchi T, Minoda S, Yabuuchi M, Akanuma Y, Akanuma H, Miyashita H, Akaoka I (1989) Plasma 1, 5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 38:723-29 CrossRef
  18. Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka L, Miyashita H (1996) Clinical usefulness of serum 1, 5-anhydroglucitol in monitoring glycaemic control. Lancet 347:1514-518 CrossRef
  19. Pal A, Farmer AJ, Dudley C, Selwood MP, Barrow BA, Klyne R, Grew JP, McCarthy MI, Gloyn AL, Owen KR (2010) Evaluation of serum 1, 5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care 33:252-57 CrossRef
  20. McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, Sarno MJ (2004) Circulating 1, 5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 27:1859-865 CrossRef
  21. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S (2006) 1, 5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29:1214-219 CrossRef
  22. Stettler C, Stahl M, Allemann S, Diem P, Schmidlin K, Zwahlen M, Riesen W, Keller U, Christ E (2008) Association of 1, 5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 31:1534-535 CrossRef
  23. Dungan KM (2008) 1, 5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 8:9-9 CrossRef
  24. Yamanouchi T, Moromizato H, Shinohara T, Minoda S, Miyashita H, Akaoka I (1992) Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1, 5-anhydroglucitol. Metabolism 41:862-67 CrossRef
  25. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, Kamada T (1995) 1, 5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18:1156-159 CrossRef
  26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461-70 CrossRef
  27. Nyback-Nakell A, von Heijne M, Adamson U, Lins PE, Landstedt-Hallin L (2004) Accuracy of continuous nocturnal glucose screening after 48 and 72 hours in type 2 diabetes patients on combined oral and insulin therapy. Diabetes Metab 30:517-21 CrossRef
  28. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ (2005) A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 7:253-63 CrossRef
  29. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644-55
  30. Fujisawa T, Ikegami H, Tsutsui T, Kawaguchi Y, Ueda H, Shintani M, Nojima K, Kawabata Y, Ono M, Nishino M, Noso S, Yamada K, Babaya N, Ogihara T (1999) Renal tubular function affects glycosuria-related urinary excretion of 1, 5-anhydroglucitol. Diabetes Care 22:863-64 CrossRef
  31. Stickle D, Turk J (1997) A kinetic mass balance model for 1, 5-anhydroglucitol: applications to monitoring of glycemic control. Am J Physiol 273:E821–E830
  32. Herman WH, Dungan KM, Wolffenbuttel BH, Buse JB, Fahrbach JL, Jiang H, Martin S (2009) Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1, 5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 94:1689-694 CrossRef
  33. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, Packer L (2002) Factors associated with oxidative stress in human populations. Am J Epidemiol 156:274-85 CrossRef
  
• 作者单位：Min Joo Kim (1)
  Hye Seung Jung (1)
  Yul Hwang-Bo (1)
  Sun Wook Cho (1)
  Hak Chul Jang (2)
  Seong Yeon Kim (1)
  Kyong Soo Park (1)
  
  1. Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul, 110-744, Republic of Korea
  2. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  
• ISSN：1432-5233

文摘

1,5-anhydroglucitol (1,5-AG) has been suggested as a marker for short-term glycemic control and postprandial hyperglycemia. However, the role of 1,5-AG in glycemic variability has not been established. The aim of this study was to demonstrate the usefulness of 1,5-AG as a marker for glycemic variability in patients with type 2 diabetes. Sixty patients with type 2 diabetes were enrolled, and a continuous glucose monitoring system (CGMS) was applied for 72?h. Continuous overlapping net glycemic action (CONGA), mean amplitude of glycemic excursion (MAGE), and mean of the daily differences (MODD) were calculated for the assessment of glycemic variability and compared with 1,5-AG. Urinary 8-iso prostaglandin F2α (8-isoPGF2α) was measured to assess oxidative stress. 1,5-AG was correlated with fasting blood glucose, HbA1c, postprandial area under the curve for glucose above 180?mg/dL (AUC-180), and mean post-meal maximum glucose (MPMG). However, 1,5-AG did not show significant correlation with CONGA-1, MAGE, and MODD (R?=??.053, P?=?0.689; R?=??.148, P?=?0.259; R?=??.123, P?=?0.350). In patients with HbA1c?≤?.0% (n?=?35), 1,5-AG was significantly correlated with HbA1c, mean glucose, postprandial AUC-180, and MPMG. However, in patients with HbA1c?>?8.0% (n?=?25), 1,5-AG did not show correlation with any glycemic markers. Oxidative stress measured as urine 8-isoPGF2α showed positive correlations with CONGA-1, MAGE, AUC-180, postprandial AUC-180, and MPMG only in men. However, 1,5-AG did not correlate with oxidative stress. Our data suggested a limited usefulness of 1,5-AG in estimating glycemic variability and oxidative stress. 1,5-AG was able to represent mean glucose and postprandial hyperglycemia only in well-controlled diabetic patients.